spacer
  Home | About CDC | Press Room | Funding | A-Z Index | Centers, Institute & Offices | Training & Employment | Contact Us
spacer
spacer CDC Centers for Disease Control and Prevention Home Page spacer
CDC en Español
spacer
Search:  
spacer
Health & Safety TopicsPublications & ProductsData & StatisticsConferences & Events
spacer
spacer
spacer
Health Alert Network
spacer
  HAN Menu
space
arrow Home
space
arrow News & Events
space
arrow Training
space
arrow IT Infrastructure
space
arrow HAN/PHIN Jurisdictions
space
arrow Other Jurisdictions
space
arrow Advanced Practice Centers
space
arrow HAN Messages Archive
space
spacer spacer
spacer
Skip Nav spacer
This is an official
CDC HEALTH ADVISORY


Distributed via Health Alert Network
Monday, October 22, 2001, 0:00 EDT (12:00 PM EDT)
CDCHAN-00040-2001-10-22-ADV-N

Protecting Investigators from Exposure to Bacillus anthracis Using Personal Protective Equipment

NIOSH personnel and other investigators at risk for exposure to Bacillus anthracis, the organism causing anthrax, should wear protective personal equipment (PPE), including respiratory devices, protective clothing, and gloves. The items described below are similar to those used by emergency personnel responding to incidents involving letters or packages.  Responders need to use greater levels of protection in responding to incidents involving unknown conditions or those involving aerosol-generating devices.

Powered Air-Purifying Respirator with Full Facepiece and High-Energy Particulate

Air (HEPA) Filters

·         The constant flow of clean air into the facepieces is an important feature of this respirator because contaminated air cannot enter gaps in the face to facepiece seal.  These respirators also give wearers needed mobility and field of vision.

·         Use respirators in accordance with a respiratory-protection program that complies with the OSHA respiratory-protection standard (29 CFR 1910.134).

·         Respiratory facepieces for NIOSH investigators will be assigned on the basis of results of quantitative fit testing.

·         Wearing a properly functioning, powered, air-purifying respirator with a full facepiece that is assigned to the wearer on the basis of quantitative fit testing will reduce inhalation exposures to 2 % or less of what they would be without wearing this type of respirator.

 

Disposable Protective Clothing with Integral Hood and Booties

·         Wearing protective clothing not only protects the skin but can eliminate the likelihood of transferring contaminated dust to places away from the work site.

·         Wear disposable rubber shoe coverings with ridged soles made of slip-resistant material over the booties of the disposable suit to reduce likelihood of slipping on wet or dusty surfaces.

·         Decontaminate all PPE immediately after leaving a potentially contaminated area.

·         Remove and discard protective clothing before removing the respirator.

 

Disposable Gloves

·         Disposable gloves made of lightweight nitrile or vinyl protect hands from contact with potentially contaminated dusts with compromising needed dexterity.

·         A thin cotton glove can be worn inside a disposable glove to protect against dermatitis, which can occur from prolonged exposure of the skin to moisture in gloves caused by perspiration.

Conclusions

·    The current  B. anthracis strains associated with the intentional exposures are  susceptible to ciprofloxacin and doxycycline, the two drugs approved for post-exposure prophylaxis to B. anthracis and recommended  as part of  initial  therapy of  inhalational or cutaneous anthrax.

·    The current strains also are susceptible to chloramphenicol, clindamycin, rifampin, vancomycin, and clarithromycin, but limited or no data exists regarding the use of these agents in the treatment or prophylaxis of B. anthracis infections. 

·    Cephalosporins should not be used for post-exposure prophylaxis or treatment of B. anthracis infections.

·    The likelihood of a beta-lactamase induction event that would increase penicillin MICs is significantly higher in infections where high concentrations of organisms are present. Thus, treatment of known B. anthracis infections with a penicillin type drug alone (i.e., penicillin G, ampicillin, etc.)  in the setting where high concentrations of organisms are present is a concern.

·    The likelihood of a beta-lactamase induction event that would increase penicillin MICs is lower when only small numbers of vegetative cells are present, such as during post exposure prophylaxis.  Thus, amoxicillin or penicillin VK may be an option for post-exposure prophylaxis where ciprofloxacin or doxycycline are contraindicated. 

·    Additional studies are in progress to assess the susceptibility of the penicillinase activity observed in these strains to beta-lactamase inhibitors.

·    Clinical experience is limited, but combination therapy with two or more antimicrobials may be appropriate in patients with severe infection.


_________________________________________________ Categories of Health Alert messages:
Health Alert- conveys the highest level of importance; warrants immediate action or attention.
Health Advisory- provides important information for a specific incident or situation; may not require immediate action.
Health Update- provides updated information regarding an incident or situation; unlikely to require immediate action.

=======================================

You have received this message based upon the information contained within our emergency notification data base. If you have a different or additional e-mail or fax address that you would like us to use please notify us as soon as possible by e-mail at healthalert@cdc.gov.

=======================================




This page last reviewed: November 10, 2003
spacer
spacer
spacer
spacer
Home | Policies and Regulations | Disclaimer | e-Government | FOIA | Contact Us
spacer
spacer
spacer Safer, Healthier People
spacer
Centers for Disease Control and Prevention, 1600 Clifton Rd, Atlanta, GA 30333, U.S.A
Tel: (404) 639-3311 / Public Inquiries: (404) 639-3534 / (800) 311-3435
spacer USA.gov: The U.S. Government's Official Web Portal DHHS Department of Health
and Human Services